Vivos Therapeutics, Inc. VVOS
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 45.21% | 33.77% | 16.05% | 18.76% | 2.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.21% | 33.77% | 16.05% | 18.76% | 2.65% |
| Cost of Revenue | 25.54% | 23.80% | 14.75% | 37.59% | 13.33% |
| Gross Profit | 60.71% | 40.78% | 16.91% | 7.12% | -4.44% |
| SG&A Expenses | 56.68% | 71.67% | 48.57% | 19.31% | 0.86% |
| Depreciation & Amortization | 131.57% | 159.15% | 125.30% | 72.53% | 31.02% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.80% | 62.59% | 42.51% | 24.22% | 4.04% |
| Operating Income | -58.47% | -99.88% | -78.11% | -30.59% | -5.48% |
| Income Before Tax | -78.97% | -123.53% | -90.65% | -36.09% | -18.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -78.97% | -123.53% | -90.65% | -36.09% | -18.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.77% | -122.38% | -90.11% | -36.09% | -18.89% |
| EBIT | -58.47% | -99.88% | -78.11% | -30.59% | -5.48% |
| EBITDA | -54.26% | -96.48% | -75.53% | -28.53% | -4.31% |
| EPS Basic | -5.30% | -15.84% | 32.04% | 66.49% | 74.38% |
| Normalized Basic EPS | -5.84% | -15.51% | 32.13% | 66.49% | 74.37% |
| EPS Diluted | -5.30% | -15.84% | 32.04% | 66.49% | 74.38% |
| Normalized Diluted EPS | -5.84% | -15.51% | 32.13% | 66.49% | 74.37% |
| Average Basic Shares Outstanding | 76.66% | 83.50% | 111.86% | 164.37% | 286.71% |
| Average Diluted Shares Outstanding | 76.66% | 83.50% | 111.86% | 164.37% | 286.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |